Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2

…, MD Percival, C Brideau, S Charleson… - … of Pharmacology and …, 2001 - ASPET
We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)
pyridine], a novel orally active agent that selectively inhibits …

The discovery of rofecoxib,[MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2 (5H)-furanone], an orally active cyclooxygenase-2 inhibitor

…, Z Wang, C Brideau, CC Chan, S Charleson… - Bioorganic & medicinal …, 1999 - Elsevier
S. Boyce and N. Rupniak … All right.s reserved. … C.; Brideau, C.; Charleson, S.;
Cromlish, W.; Ethier, D.; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R.; Guay, J.; …

Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

S Kargman, S Charleson, M Cartwright, J Frank… - Gastroenterology, 1996 - Elsevier
BACKGROUND & AIMS: In the gastrointestinal tract, prostaglandins are implicated as important
mediators of normal physiological processes. Prostaglandin G/H synthase (PGHS) is the …

Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and …

CC Chan, S Boyce, C Brideau, S Charleson… - … of Pharmacology and …, 1999 - ASPET
The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX involved in
inflammation and that COX-1 is the major isoform responsible for the production of prostaglandins (…

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.

…, L Hearn, JA Heibein, S Charleson… - The Journal of …, 1993 - rupress.org
The intracellular distribution of the enzyme 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating
protein (FLAP) in resting and ionophore-activated human leukocytes has been …

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

…, S Boyce, C Brideau, S Charleson… - British journal of …, 1997 - Wiley Online Library
… k 2 value of 0.11±0.06 s −1 for the first order rate constant for formation of a tightly bound
enzyme‐inhibitor complex. Comparable values of 62±26 μM and 0.06±0.01 s −1 , respectively, …

5‐lipoxygenase‐activating protein is an arachidonate binding protein

…, M Abramovitz, ME Cox, E Wong, S Charleson… - FEBS …, 1993 - Wiley Online Library
… 5-Lipoxygenase-activating protein (FLAP) is an 1 S-kDa integral membrane protein which is
… However, the mechanism by which FLAP activates S-LO has not been determined. We have …

2-Pyridinyl-3-(4-methylsulfonyl) phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors

RW Friesen, C Brideau, CC Chan, S Charleson… - Bioorganic & medicinal …, 1998 - Elsevier
A series of novel 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines has been synthesized and
evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1, and …

Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors, using sensitive microsomal and …

D Riendeau, S Charleson, W Cromlish… - Canadian journal of …, 1997 - cdnsciencepub.com
… The inhibition by flurbiprofen was stereoselective, the (S)-flurbiprofen being 600-fold more
… IC50 values ranged from 0.6 nM for (S)-flurbiprofen to 500 µM for salicylic acid. L-745,296, a …

From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

…, C Bayly, M Belley, CC Chan, S Charleson… - Bioorganic & Medicinal …, 1996 - Elsevier
A series of potent and highly selective cyclooxygenase-2 inhibitors have been prepared by
replacing the benzoyl group of indomethacin with a 4-bromobenzyl group, and by extending …